Gemigliptin Tartrate Sesquihydrate
Gemigliptin tartrate sesquihydrate is an oral antidiabetic medication used in the management of type 2 diabetes mellitus. It belongs to the class of drugs known as DPP-4 (dipeptidyl peptidase-4) inhibitors. Gemigliptin works by enhancing the body's natural ability to lower blood sugar levels by increasing insulin release and decreasing glucagon levels, which helps regulate glucose levels in the blood.Type 2 Diabetes Mellitus: Used to improve glycemic control in adults with type 2 diabetes, either alone or in combination with other antidiabetic agents.
-Standard Dosage: Typically, 50 mg taken orally once daily. Dosage may be adjusted based on individual patient needs and response to treatment. -Renal Impairment: Dose adjustments may be necessary for patients with renal impairment.
-Hypersensitivity: Contraindicated in individuals with a known hypersensitivity to gemigliptin or any of its excipients. -Type 1 Diabetes Mellitus: Not indicated for use in type 1 diabetes or for the treatment of diabetic ketoacidosis.
-Renal Function: Monitor renal function regularly, especially in patients with pre-existing renal conditions. -Pancreatitis: Caution in patients with a history of pancreatitis. -Pregnancy and Lactation: Safety during pregnancy and breastfeeding has not been established; use only if clearly needed and prescribed by a healthcare provider.
-Common: Headache, upper respiratory tract infection, nasopharyngitis, gastrointestinal discomfort. -Serious: Risk of pancreatitis, hypersensitivity reactions, hypoglycemia when used in combination with other antidiabetic agents.
-CYP3A4 and CYP2D6 Inhibitors: May interact with medications that affect CYP3A4 and CYP2D6 enzyme activity. -Antidiabetic Agents: May enhance the effects of other antidiabetic drugs, potentially increasing the risk of hypoglycemia.
